Original Publication Date: 1 November, 2015
Publication / Source: Immunotherapy
Authors: Amer Assal, Justin Kaner, Gopichand Pendurti & Xingxing Zang
Manipulation of co-stimulatory or co-inhibitory checkpoint proteins allows for the reversal of tumor-induced T-cell anergy observed in cancer. The field has gained credence given success with CTLA-4 and PD-1 inhibitors. These molecules include immunoglobulin family members and the B7 subfamily as well as the TNF receptor family members. PD-L1 inhibitors and LAG-3 inhibitors have progressed through clinical trials.